IP Library Granted Patent US 12,108,979
Granted Patent B2
US 12,108,979 · App. 18/411,460 · Granted Oct 8, 2024

Systems and methods for improving sleep with therapeutic nasal treatment

Inventor: David Townley (Clare, IE)
Assignee: Neurent Medical Limited
A61B18/148A61B2018/00327A61B2018/00434A61B2018/00583A61B2018/1467
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,108,979
App. No.
18/411,460
Granted
Oct 8, 2024
Kind
B2
Abstract

The invention generally relates to systems and methods for improving sleep by treating at least one of rhinitis, congestion, and/or rhinorrhea to thereby reduce or eliminate symptoms associated therewith, including, but not limited to, nasal congestion, coughing, sneezing, and nasal or throat irritation and itching.

Claims (23)

1. A method for improving a patient's sleep by treating at least one of congestion, obstruction, and blockage within a sino-nasal cavity of the patient, the method comprising:

advancing an end effector of a treatment device into the sino-nasal cavity of the patient, the end effector being positioned at a distal portion of a shaft of the treatment device, wherein the end effector comprises:

an array of bipolar electrodes provided thereon and comprising at least first electrode that is spaced apart from a separate and distinct second electrode along a length of the end effector, wherein each of the first and second electrodes comprises an active state and an inactive state and comprises a separate respective location on the end effector and extends beyond surface of the shaft, wherein each of the first and second electrodes is configured to deliver temperature-controlled radiofrequency (RF) energy to tissue at one or more target sites within the nasal cavity of the patient; and

at least one temperature sensor arranged relative to the array of electrodes;

positioning the end effector at a target site to thereby cause at least the first and second electrodes to be in direct contact with tissue at a target site within the sino-nasal cavity; and

delivering RF energy from the first and second electrodes to tissue at the target site at a level and for a period of time sufficient to cause reduced engorgement of the tissue and thereby increase volumetric flow through an associated nasal passage of the patient to improve nasal breathability of the patient;

wherein delivery of RF energy is controlled via a console unit operably coupled to the array of bipolar electrodes and the at least one temperature sensor based, at least in part, on feedback received from the at least one temperature sensor in order to maintain a predetermined temperature of the tissue at the target site.

2. The method of claim 1 , wherein the target site comprises an inferior turbinate within the nasal cavity and the tissue comprises submucosal tissue associated with the inferior turbinate.

3. The method of claim 1 , wherein the console unit is operably coupled to an energy generator configured to generate RF energy to be delivered by the first and second electrodes.

4. The method of claim 3 , wherein the RF energy comprises at least bipolar RF energy.

5. The method of claim 1 , wherein the array of electrodes comprises at least four electrodes.

6. The method of claim 5 , wherein the array of electrodes comprises at least eight electrodes.

7. The method of claim 1 , wherein the console unit is configured to receive one or more temperature readings from the at least one temperature sensor and process the readings to determine a level of RF energy to be delivered by the first and second electrodes that is sufficient to maintain a temperature of the tissue at the target site below a predetermined threshold maximum temperature of tissue during delivery of energy to ensure that application of the RF energy results in the desired effect of reduced engorgement of the tissue at the target site for a given treatment application.

8. The method of claim 7 , wherein the console unit is configured to monitor temperature of tissue at the target site during delivery of RF energy thereto based on temperature readings from the at least one temperature sensor and further monitor an elapsed time during delivery of RF energy to tissue at the target site.

9. The method of claim 7 , wherein the console unit is configured to provide, via a display, feedback information to an operator during delivery of RF energy, wherein said feedback information comprises at least an elapsed time during delivery of RF energy to tissue at the target site.

10. The method of claim 9 , wherein the display is a touchscreen monitor.

11. The method of claim 7 , wherein the console unit comprises a hardware processor coupled to non-transitory, computer-readable memory containing instructions executable by the processor to cause the console unit to automatically control and adjust RF energy output from the array of electrodes based, at least in part, on a predetermined elapsed time period and the predetermined threshold maximum temperature.

12. The method of claim 11 , wherein the predetermined threshold maximum temperature is less than 90° C.

13. The method of claim 11 , wherein the predetermined threshold maximum temperature is greater than 37° C. and less than 90° C.

14. The method of claim 11 , the predetermined elapsed time period is from about 1 second to about 20 seconds.

15. The method of claim 14 , wherein the predetermined elapsed time period is from about 5 seconds to about 10 seconds.

16. The method of claim 14 , wherein the predetermined elapsed time period is from about 8 seconds to about 10 seconds.

17. The method of claim 14 , wherein the predetermined elapsed time period is from about 10 seconds to about 12 seconds.

Assignments (2)
SECURITY INTEREST Recorded Oct 18, 2024
From: NEURENT MEDICAL LIMITED
To: CLARET EUROPEAN SPECIALTY LENDING COMPANY III, S.A R.L.
Reel/Frame 068942/0887 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2024
From: TOWNLEY, DAVID
To: NEURENT MEDICAL LIMITED
Reel/Frame 067076/0771 →
Continuity (3)
Continuation 17225560 · Apr 8, 2021
Provisional Application 63007584 · Apr 9, 2020
Related Publication 20240138904A1 · May 2, 2024
Cited By (2)
US 12,357,817 US 12,636,073